...
首页> 外文期刊>International Journal of Leprosy and Other Mycobacterial Diseases >Why relapse occurs in PB leprosy patients after adequate MDT despite they are Mitsuda reactive: lessons form Convit's experiment on bacteria-clearing capacity of lepromin-induced granuloma.
【24h】

Why relapse occurs in PB leprosy patients after adequate MDT despite they are Mitsuda reactive: lessons form Convit's experiment on bacteria-clearing capacity of lepromin-induced granuloma.

机译:为何尽管Mitsuda具有反应性,但在适当的MDT后PB麻风病患者会发生复发:Convit关于麻风病性肉芽肿清除细菌能力实验的教训。

获取原文
获取原文并翻译 | 示例

摘要

It is amazing how after years of scientific research and therapeutic progress many simple and basic questions about protective immunity against Mycobacterium leprae remain unanswered. Although the World Health Organization (WHO) has recommended short-term multidrug therapy (WHO/MDT) for the treatment of paucibacillary (PB) leprosy patients, from time to time several workers from different parts of the globe have reported inadequate clinical responses in a few tuberculoid and indeterminate leprosy patients following adequate WHO/MDT despite the fact that they are Mitsuda responsive. A few borderline tuberculoid patients harbor acid-fast bacilli (AFB) in their nerves for many years even though they become clinically inactive following MDT, a fact which has been ignored by many leprosy field workers. Keeping these patients in mind, we have attempted to investigate the cause of the persistence of AFB in PB cases and have looked into the question of why Mitsuda positivity in tuberculoid and indeterminate leprosy patients, as well as in healthy contacts, is not invariably a guarantee for protectivity against the leprosy bacilli. We have: a) analyzed the histological features of lepromin-induced granulomas, b) studied the bacteria-clearing capacity of the macrophages within such granulomas, and c) studied the in vitro leukocyte migration inhibition factor released by the blood leukocytes of these subjects when M. leprae sonicates have been used as an elicitor. The results of these three tests in the three groups of subjects have been compared and led us to conclude that the bacteria-clearing capacity of the macrophages within lepromin-induced granuloma (positive CCB test) may be taken as an indicator of the capability of elimination of leprosy bacilli and protective immunity against the disease. This important macrophage function is not invariably present in all tuberculoid and indeterminate leprosy patients or in all contacts even though they are Mitsuda responsive and are able to show a positive leukocyte migration inhibition (LMI) test. It is likely but not certain that this deficit of the macrophage is genetically predetermined and persists after completion of short-term WHO/MDT. Thus, after discontinuation of treatment slow-growing, persisting M. leprae multiply within macrophages leading to relapse.
机译:令人惊讶的是,经过多年的科学研究和治疗进展,许多关于麻风分枝杆菌保护性免疫的简单而基本的问题仍未得到解答。尽管世界卫生组织(WHO)建议使用短期多药疗法(WHO / MDT)治疗麻风杆菌(PB)麻风病患者,但不时有来自全球不同地区的几名工人报告说,很少有结核病和不确定的麻风病患者经过适当的WHO / MDT治疗,尽管他们对三田有反应。少数交界性结核患者即使在MDT后变得临床不活跃,多年来仍在神经中带有抗酸杆菌(AFB),这一事实已被许多麻风病现场工作者所忽略。考虑到这些患者,我们试图调查PB患者中AFB持续存在的原因,并探讨了为什么结核和不确定性麻风患者以及健康接触者中的Mitsuda阳性始终不能得到保证的问题保护麻风杆菌。我们已经:a)分析了由麻风蛋白引起的肉芽肿的组织学特征,b)研究了这些肉芽肿中巨噬细胞的细菌清除能力,以及c)研究了这些受试者的血液白细胞在体外释放的体外白细胞迁移抑制因子。麻风分枝杆菌的超声波已经用作引发剂。比较了三组受试者的这三种测试结果,并得出结论,认为可以将麻风病诱发的肉芽肿中巨噬细胞的细菌清除能力(CCB阳性试验)作为清除能力的指标。麻风杆菌的感染和对这种疾病的保护性免疫。尽管重要的巨噬细胞功能对三田有反应,并且能够显示出阳性的白细胞迁移抑制(LMI)测试,但并非所有结核病和不确定的麻风病人或所有接触者都始终存在这种重要的巨噬细胞功能。可能但不能确定巨噬细胞的这种缺陷在遗传上是预先确定的,并且在短期WHO / MDT完成后仍然存在。因此,停止治疗缓慢生长后,持续存在的麻风分枝杆菌在巨噬细胞内繁殖,导致复发。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号